探讨多西他赛联合奥沙利铂及卡培他滨在晚期胃癌姑息化疗的疗效价值。

收集2011年1月至2016年12月期间接受姑息化疗的胃癌晚期患者60例，采用随机数字表法将其分为对照组(n＝30)与观察组(n＝30)，对照组患者给予奥沙利铂及卡培他滨姑息化疗治疗，观察组患者给予多西他赛联合奥沙利铂及卡培他滨联合药物姑息化疗，采用Spss15.0软件处理数据，两组患者近期疗效、不良反应采用(例，%)表示，χ²检验；远期疗效采用均数±标准差表示，独立t检验，P<0.05为差异具有统计学意义。

对照组患者缓解率为26.7%，观察组患者缓解率为56.7%；观察组患者的胃癌进展时间及胃癌存在时间均低于对照组，差异具有统计学意义(P<0.05)。两组不良反应情况差异无统计学意义(P>0.05)。

多西他赛联合奥沙利铂及卡培他滨在晚期胃癌患者姑息化疗中疗效肯定，患者满意度高，值得临床推广应用。

To investigate the clinical efficacy of docetaxel combined with oxaliplatin and capecitabine in treating advanced gastric cancer.

60 patients with advanced gastric cancer received neoadjuvant chemotherapy in our hospital from January 2011 to December 2016, whom were randomly divided into the control group (n=30) and the observation group (n=30). Patients in the control group was treated with oxaliplatin and capecitabine, while patients in the observation group was given docetaxel combined with oxaliplatin and capecitabine for palliative chemotherapy.Spss15.0 softwarewas used for data analysis.The short-term clinical outcomewere presented as mean+ standard deviation and were examined by using t test.The incidence of side effects were expressed as %, and were compared with χ² test. P<0.05 was considered as significant difference.

The remission rate in the control group was 26.7%, while the remission rate in the observation group was 56.7%.The time of progress and the survival time in the observation group were better than those in the control group respectively, with significant difference (P<0.05). There was no significant difference in terms of adverse reactions between the observation group and the control group (P>0.05).

Therapeutic effect of docetaxel combined with oxaliplatin and capecitabine in the palliative chemotherapy of advanced gastric cancer is positive, with patient’s satisfaction. It is worthy of clinical application.